Research & Development: Page 88
-
PharmaVoice Team/PharmaVoice
Letter from the Editor
Leadership development is a concern for all executive management teams, no matter the size of their company or their business model. It’s vitally important to have processes in place that foster talent development for the next generation of leaders. The subject of this month’s Forum had been on t...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
March 15-16 Prescription Drug Pricing InterContinental The Barclay, New York PharmaVOICE subscribers are eligible for a $200 discount; register using priority code 656PHVC. For more information, contact Edward Santelices, American Conference Institute, at 212-352-3220, ext. 239, e-mail e.santelic...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
What's New
CommonHealth Celebrates Opening Of Paris Office The move is designed to allow CommonHealth to broaden its offerings to an increasingly global clientele. CommonHealth has opened an office in Paris. The move is designed to allow CommonHealth to broaden its offerings to an increasingly global client...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
Thomson Scientific Expands Pharmaceutical Regulatory Intelligence Coverage Thomson Scientific announces that three new country modules, India, Israel, and Turkey, are now available in IDRAC, the global pharmaceutical regulatory intelligence database. IDRAC is recognized by regulatory professional...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Dr. Lou Barbato Tikvah Names VP, Clinical R&D, and Chief Medical Officer Atlanta-based Tikvah Therapeutics has named Lou Barbato, M.D., as VP, clinical research and development, and chief medical officer. Tikvah acquires, develops, and commercializes novel therapeutics related to ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Moving Science Forward -- Dr. Russell M. Medford
By Kim Ribbink With a pioneering spirit that has led him to tackle emerging fields of science, Russell M. Medford, M.D., Ph.D., is striving to ensure that AtheroGenics, the company he cofounded in 1993, is creating breakthrough medications for chronic inflammation. March 2007 Entrepreneurial spir...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
EDC: Crossing the Chasm
In the figurative but practical language of Silicon Valley marketing guru Geoffrey Moore, the leading EDC companies have “crossed the chasm” from the fluidity of the early adopter market to the more established needs of the mainstream market. This may be the dream of many an EDC company CEO, but ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Overcoming Challenges to the Path to Combination Product Development Combination products have the potential to vastly improve medical care, making treatment more effective and safe, as well as improving compliance for patients. But because of the novelty and complexity of such products, companie...
By Christine Ford • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
Table of Contents March 2007 On the Cover Leadership Development: The Next Generation Industry leaders have to manage a complex and evolving environment. A company’s success will depend on its ability to identify and develop these executives. Features The Making of a Successful Publication Strate...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Looking Ahead: The Deficit Reduction Act
A prescription to adopt forward-looking strategies and ensure corporate and regulatory compliance excellence As government healthcare spending increases, Congress, states, and agencies will continue to put cost management and containment on their agendas. Given this reality, it is important to bu...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
On the Calendar February 2007 Industry Events Your Source for Life-Sciences Events and Conference Information Professional education is an ongoing endeavor for most executives. PharmaVOICE has partnerships with every major conference provider serving the life-sciences industry. PharmaVOICE is dis...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Talent Pool Executive Appointments and Promotions Pharma POOL Mark Acosta Diana Bodden Anne Carlson Robert Corrie Cynthia Devereux Barry Gorewit Patrick Gose Darbi James Lawrence Kristoff Richard Laurie Randy Lawson Dr. David Levin Rita Myers June Nguyen Lynda Parker Bradley Pierson John Schillo ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Medicare Part D: It’s Crunch Time … Again Manufacturers are facing déjà vu with Part D. While the 2006 Part D year recently came to a close and the 2007 Part D year is nascent, crucial decisions related to 2008 Part D are right around the corner. The Centers for Medicare and Medicaid Services (CM...
By Kevin Barnett • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
UpFront
PDUFA Update FDA Requests $87.4 million increase The FDA has put before Congress its recommendations for reauthorizing the Prescription Drug User Fee program (PDUFA). If adopted, PDUFA IV — the fourth reauthorization since the program began almost 15 years ago — would significantly broaden and up...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Greg Sarian discusses executive trading rules. Contributed by Greg Sarian In an age when corporate scandals are top of mind and full financial disclosure is a must, executives may find it difficult to trade their company’s stock without raising eyebrows about how their insider knowledge may have ...
By Greg Sarian • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Life-Sciences Marketers Capitalize on Media Engagement Level A recent survey — Marketing to Life Scientists 2006: Capitalizing on Media Engagement — from BioInformatics LLC found that life scientists who are highly engaged differ significantly from less engaged scientists in their media preferenc...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Stroke: Bats and Snakes May Hold the Answer
By Cynthia Borda A decade ago, the introduction of tPA was a major step forward in stroke treatment, and the hope was that other approaches and additional therapies would soon be available. Unfortunately, the next generation of products has yet to materialize. Every 45 seconds, someone in the Uni...
By Cynthia Borda • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Flying Sky High -- Rajesh C. Shrotriya
With enormous enthusiasm and a joie de vive, Dr. Rajesh Shrotriya, chairman and CEO of Spectrum Pharmaceuticals, is instilling his employees with the same gusto for development of new drugs. Propelled by a joy of work and a commitment to remaining focused on a task until it is accomplished, Rajes...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Targeted Media Messaging: Patient Recruitment Marketing
By Kim Ribbink Patient recruitment is widely considered to be the most costly and time-consuming aspect of clinical trials, and the need to improve the process is pressing. One key aspect to achieving this goal is the use of appropriate media as part of a marketing campaign to improve patient enr...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
Blue Spoon Releases Ecosystem Solution For Pharma Sales Effectiveness Blue Spoon Consulting has released a marketing ecosystem-based solution for pharmaceutical sales effectiveness. The new design links the context, content, and process of the virtual and physical domains of pharmaceutical sales ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Raise Your Voice -- Letters
The Future of eClinical Recently, I had the opportunity to participate in an eClinical conference sponsored by etrials Inc. Clearly, among the participants at the event — both sponsors and trial partners –there was an underlying consensus that we understand the benefits of real-time data, know th...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
On the Cover The age of personalized medicine The study of genomics holds promise for helping to identify better drug targets and guiding companies in designing trials. The hope is that pharmacogenomics will lead to more targeted therapies. Features Patient recruitment marketing Patient recruitme...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Is there anything more personal than healthcare? Whether we are talking about medical records or medicine — personalization is coming into vogue, albeit with a caveat on privacy protection. According to a recent Wall Street Journal Online/Harris Interactive Health-Care poll, when it comes to the ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
PharmaTrax Sales, Marketing, and R&D Trends from Industry Analysts Scientific Expertise and Good Value Are Important When Choosing a CRO The primary factors pharmaceutical and biotechnology companies consider when selecting a CRO are the strength of its scientific expertise and the cost/value...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Contributed by James Rogers Merging Clinical-Trials Safety and Pharmacovigilance The Winds of change in safety monitoring In November 2003, Mark B. McClellan, M.D., Ph.D., a former commissioner with the Food and Drug Administration, made the comment: “…there is no such thing as a completely safe ...
By James Rogers • Jan. 2, 2008
Previous
